TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Improved Cognitive Function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in pepsinogen level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: 24 hour sputum clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Quality of Life SGRQ
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Intracranial progression-free
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: circulating tumor DNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes of brain networks measured by BOLD-fMRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes of white matter fibers measured by DTI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Exercise-induced Perfusion Defect Size (PDS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Exercise-induced Total Perfusion Deficit (TPD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mid-term disease progression in terms of overall motor symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mid-term disease progression in terms of bradykinesia and rigidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Clinical Improvement in NRS Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of Pulmonary Complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time to Alleviation of All ARVI Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic Comparison
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose formulation safety
Endpoint domain: Adverse events/effects
Primary endpoint: Intensity of posttraumatic symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Success to Quit (STQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Cigarettes Per Day (CPD) From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Point Prevalence Abstinence (PPA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients Who Are Alive and Have Not Developed Any Event
Endpoint domain: Mortality/survival
Primary endpoint: Feasibility as assessed by recruitment response rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in behavioral sleep problems
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in Cerebral Blood Flow (CBF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of hypogammaglobinemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Larynx preservation free survival
Endpoint domain: Mortality/survival
Primary endpoint: Percent Reduction Over Placebo for Partial Onset Seizure Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 50% Responder Rate for Partial Onset Seizure Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Corneometer CM 825 measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Lactobacillus level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HPV vaccine-type-specific seroconversion rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Fraction of cells positive for apoptosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug target engagement biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recollection of experience
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Tear Meniscus Height (TMH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Tear Lipid Layer Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Non-Invasive Tear Film Break-Up Time (NIBUT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of dioxin and related compounds in adipose tissue and liver samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of participants successfully completing HDF without interruption of therapy during Dialysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants by Level of Effectiveness of Disposable Tubing during and after Dialysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction ratio of β2-Microglobulin during and after Dialysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: serum lactate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Toxic Effects
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of acute pancreatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Montgomery-Asberg Depression Rating Scale (MADRS) Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Blood level concentrations of JNJ-41443532
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in self-reported perpetration of Sexual Violence and Adolescent Relationship Abuse
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: PT and PTT levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coagulation Factors levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CDAI (Clinical Disease Activity Index) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With a Positive Response to Tetanus Toxoid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Groton Maze Learning Task (Total Errors)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Anxiety Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Young Adult Behavioral Scale (YABS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reactive-Proactive Aggression Questionnaire (RPQ)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Depression Anxiety Stress Scale - 21 items (DASS-21)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Motivated strategies for Learning Questionnaire (MSLQ)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Emotion Regulation Questionnaire (ERQ)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Difficulties in Emotion Regulation Scale - Short Form (DERS-SF)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in anxiety level scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Geometric Mean concentration of anti-HPV16/18 IgG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Difference in serum TNFα level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Difference in fibrinogen level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Bone Mineral Density (BMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of patients considered in failure of outpatient alcohol detoxification
Endpoint domain: Adverse events/effects
Primary endpoint: Muscle power in the lower limbs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Worst Pain Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall response based on skin-weighted assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Causality of each adverse event and grading severity
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose (MTD) of abiraterone acetate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with stable disease for ≥ 24 weeks or objective response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Composition of Microorganisms in stool after probiotic intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Short-chain fatty acids in feces of patients after chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Frequency and severity of Adverse effects during Chemotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: Physician's DPN Lesions Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: numbers of EPCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Vestibule Depth Measurement Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve of the analyte in plasma from time zero to infinity (AUC 0-infinity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bath Ankylosing Spondylitis Spinal Metrology Index (BASMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Initiation of long term contraception
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Cessation of Epistaxis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mucin levels in tears
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with cardiovascular cause of death
Endpoint domain: Mortality/survival
Primary endpoint: Number of participants with arrhythmic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of participants with major heart failure events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence of eCD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in daily insulin need
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Binet-Kamat Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric Mean Fold Rise From Baseline in VZV gpELISA Antibody Titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Titers of H1N1-specific Influenza Virus Antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Titers of H3N2-specific Influenza Virus Antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Titers of B-Yamagata-specific Influenza Virus Antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Size of the ablation zone in histopathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OMNI scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Emotional Reactivity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patient Sleep Quality
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Invasive disease-free survival (iDFS)
Endpoint domain: Mortality/survival
Primary endpoint: Lens Thickness (LT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biodistribution of the radiotracer 18F-ASIS estimated by PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dosimetry of the radiotracer 18F-ASIS estimated by PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Count of Participants With a Partial Response (PR) and Complete Response (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants With Suboptimal and Optimal Levels of Vitamin D
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in the Ratio of the Specific Striatal [123I]B-CIT Uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Maximum systolic arterial pressure (SAP) reductions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Uterine involution curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: TIMI Flow Grade 3 of MI Culprit Vessel at Initial Angiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ST-segment Elevation Resolution Pre PCI ≥70%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ramipril concentration in blood serum (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pseudoword reading test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Factor VIIa concentration in patient plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of indocyanine green
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Willing to Complete 5 Days of tDCS or Sham
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change of SOFA Score at hour 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Had IUD Removed Within 6 Months
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of patients with symptomatic hypoglycemia event
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Body Circumference Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Weight of Body Fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: angiographical in-stent minimal lumen diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Detection of histologically confirmed Cervical Intraepithelial Neoplasia grade 1 or worse (CIN1+)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean 7-day Angioedema Activity Score (AAS7)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of a 7-day Angioedema Activity Score (AAS7) Greater Than 0 Across All Treatment Visits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Recurrence of Pseudomonas (P.) Aeruginosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Ability to maintain oxygen saturation at or above 90%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of participants with Intrahepatic fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Hopkins Motor/Vocal Tic Scale (HM/VTS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Time-Matched Difference in QTcF Intervals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Receptor Binding (Vt)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Receptor Binding Corrected for Plasma (Vt/fp)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mechanical Ventilation Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of Participants Experiencing Any Treatment Emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Experiencing Adverse Events Related to Idelalisib
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Permanently Discontinued Idelalisib Due to an Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: 3-day Recall Measure of Doses Taken
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analog Scale Measure of Adherence to ART
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Peripapillary RNFL Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Macular Ganglion Cell-Inner Plexiform Layer Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage Change in ON Head Cup-to-Disc Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Diameter of the Internal Cervical os
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Surgical cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Infectious events
Endpoint domain: Adverse events/effects
Primary endpoint: Time to First Confirmed Clinical Relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absence of major adverse cardiac and cerebral vascular events (MACCE)
Endpoint domain: Mortality/survival
Primary endpoint: Change in Constant score (CS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Postprandial Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tolerance and acceptability of terazosin
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Level of sexual functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Radiation dose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of spinal cord lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: GABA/Glutamate concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analog Scale of Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient global assessment (PGA)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: In-brace Cobb angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with alcohol consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in percentage overweight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of fluorescent adenomatous polyps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Image quality of echocardiographic data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of MCE following AI-700 dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Liver regeneration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of severity of bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Overall Asthma Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV-1 RNA in plasma at week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV-1 RNA in plasma at week 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of Insulin Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: MR Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with >=25% increase in fibrosis score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time from injection of Midazolam to oocyte aspiration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment-Related Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Hand eczema severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Count/Percentage of Patients Experiencing Paclitaxel-induced Pain Syndrome
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Curve Summary of Worst Pain in the Last 24 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Mitochondrial Network Complexity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 8 Week Completion Rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in sperm motility from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change in sperm count from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes